IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.952
AS - Asia 13.516
EU - Europa 12.082
SA - Sud America 3.204
Continente sconosciuto - Info sul continente non disponibili 355
AF - Africa 344
OC - Oceania 29
Totale 54.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.761
SG - Singapore 4.717
IT - Italia 3.689
CN - Cina 3.298
RU - Federazione Russa 3.206
BR - Brasile 2.506
VN - Vietnam 1.926
GB - Regno Unito 1.406
BD - Bangladesh 1.049
HK - Hong Kong 949
DE - Germania 829
CA - Canada 782
FR - Francia 505
UA - Ucraina 471
SE - Svezia 383
FI - Finlandia 336
IN - India 327
IE - Irlanda 268
AR - Argentina 248
MX - Messico 248
NL - Olanda 205
TR - Turchia 187
PL - Polonia 183
ID - Indonesia 170
IQ - Iraq 137
ES - Italia 134
EC - Ecuador 126
ZA - Sudafrica 126
DK - Danimarca 123
JP - Giappone 118
IL - Israele 117
PK - Pakistan 99
CO - Colombia 86
AT - Austria 84
VE - Venezuela 62
UZ - Uzbekistan 61
MA - Marocco 57
AE - Emirati Arabi Uniti 54
LT - Lituania 48
PY - Paraguay 47
CL - Cile 44
PE - Perù 36
SA - Arabia Saudita 36
PH - Filippine 34
EG - Egitto 31
MY - Malesia 31
CR - Costa Rica 30
KE - Kenya 29
TN - Tunisia 29
CH - Svizzera 27
UY - Uruguay 23
AZ - Azerbaigian 22
DZ - Algeria 22
EU - Europa 21
BE - Belgio 20
BO - Bolivia 20
JO - Giordania 20
NP - Nepal 20
AU - Australia 18
HN - Honduras 18
JM - Giamaica 17
GT - Guatemala 15
RO - Romania 15
AL - Albania 14
DO - Repubblica Dominicana 14
KZ - Kazakistan 14
OM - Oman 13
TH - Thailandia 13
TW - Taiwan 12
CZ - Repubblica Ceca 11
NI - Nicaragua 11
SK - Slovacchia (Repubblica Slovacca) 11
AM - Armenia 10
GR - Grecia 10
HU - Ungheria 10
IR - Iran 10
PA - Panama 10
PT - Portogallo 9
BB - Barbados 8
BY - Bielorussia 8
KW - Kuwait 8
LB - Libano 8
MC - Monaco 8
NZ - Nuova Zelanda 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
MD - Moldavia 7
PR - Porto Rico 7
SN - Senegal 7
BH - Bahrain 6
CG - Congo 6
ET - Etiopia 6
GE - Georgia 6
HR - Croazia 6
KR - Corea 6
LV - Lettonia 6
MK - Macedonia 6
QA - Qatar 6
RS - Serbia 6
Totale 54.030
Salva come PNG Salva come JPEG
Città #
Dallas 4.547
Singapore 2.470
Ashburn 1.642
San Jose 1.612
Chicago 1.317
Beijing 1.273
Los Angeles 1.114
Hong Kong 880
Council Bluffs 683
Ho Chi Minh City 614
Moscow 588
Salt Lake City 557
Southend 540
Milan 539
New York 518
Buffalo 460
Chandler 453
Fairfield 416
Hanoi 380
Houston 350
Rome 334
Woodbridge 334
San Mateo 332
Santa Clara 317
Tampa 314
Wilmington 290
Seattle 281
The Dalles 277
São Paulo 264
Dublin 258
Elk Grove Village 251
Ann Arbor 243
Cambridge 242
Falls Church 232
Lauterbourg 231
Hefei 221
Boardman 218
Helsinki 208
Ottawa 198
Jacksonville 193
Dearborn 162
Pisa 159
Beauharnois 156
Portsmouth 156
Warsaw 155
Orem 151
Montreal 150
Phoenix 150
Munich 142
Stevenage 142
Florence 134
Sterling 123
Brooklyn 121
Mexico City 121
Frankfurt am Main 119
Dong Ket 117
Lancaster 116
London 111
Lawrence 107
Tel Aviv 104
Denver 100
Tokyo 100
Miami 98
Toronto 98
Atlanta 95
Poplar 93
Amsterdam 92
Istanbul 90
Chennai 87
Rio de Janeiro 87
Johannesburg 84
Stockholm 81
Da Nang 78
Naples 78
Nuremberg 78
Columbus 73
Dulles 72
Bologna 68
Turin 66
Detroit 60
Haiphong 59
Figino 58
Belo Horizonte 57
Manchester 57
San Diego 56
Tashkent 56
Boston 53
Lappeenranta 53
Washington 53
Kansas City 51
Palermo 51
Turku 48
Brasília 46
Genoa 45
San Francisco 45
Baghdad 44
Quito 44
Charlotte 43
Curitiba 43
Querétaro 43
Totale 31.570
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.851
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.710
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.585
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 743
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 702
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 625
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 469
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 420
A simple echocardiographic score to rule out cardiac amyloidosis 395
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 387
A simple echocardiographic score to rule out cardiac amyloidosis 379
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians 375
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 337
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 336
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 334
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 321
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 319
Adrenergic activation in heart failure: blockade or rebalance? 316
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 314
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 312
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 309
Eligibility for vericiguat in a real‐world, contemporary heart failure population 309
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 308
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 306
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 304
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 304
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 301
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 301
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 299
[Ten perspectives for research and innovation in cardiac amyloidosis] 299
Screening the health status of people working in a university 297
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 295
How to take arms against central apneas in heart failure 291
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 289
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 285
Sex-related differences in chronic heart failure 285
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 281
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 281
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 279
RNA-targeting and gene editing therapies for transthyretin amyloidosis 279
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 278
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 278
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 277
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 274
Cardiac light-chain deposition disease relapsing in the transplanted heart 274
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 271
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 270
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 269
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 269
Atrial amyloidosis: mechanisms and clinical manifestations 268
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 266
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 266
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 265
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 265
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 264
Update sui biomarcatori nello scompenso cardiaco. 263
Valve disease in cardiac amyloidosis: an echocardiographic score 262
Disease features and management of cardiomyopathies in women 261
Biomarkers for the diagnosis and management of heart failure: New frontiers 261
null 258
Biomarkers for the diagnosis and management of heart failure 255
null 253
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 252
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 248
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 248
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 247
The search for efficient diagnostic and prognostic biomarkers of heart failure 246
Renin profiling predicts neurohormonal response to sacubitril/valsartan 245
Role of Imaging in Cardiomyopathies 243
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 243
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 243
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 242
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 241
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 241
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 241
Valvular heart disease in patients with cardiac amyloidosis 240
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 239
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 238
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 236
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 236
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 236
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 230
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 230
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 228
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 228
null 228
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 228
Prognostic value of plasma Renin activity in heart failure. 227
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 227
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 227
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 226
null 226
Cardiac amyloidosis: Innovations in diagnosis and treatment 224
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 224
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 224
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 224
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 223
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 222
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 221
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 220
Totale 32.891
Salva come PNG Salva come JPEG
Categoria #
all - tutte 258.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 258.246
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.474 0 0 80 198 75 69 202 338 142 199 36 135
2022/20231.348 110 112 62 143 166 178 36 120 253 30 83 55
2023/20241.338 76 36 239 102 73 120 105 65 51 75 55 341
2024/202513.757 112 134 492 202 421 496 1.194 2.132 818 1.995 3.124 2.637
2025/202629.429 1.464 4.071 3.936 3.830 2.783 1.795 2.691 1.329 1.783 1.903 2.013 1.831
2026/20271.919 769 909 241 0 0 0 0 0 0 0 0 0
Totale 54.482